Safety Study of Afatinib for Brain Cancer

Brain Cancer Clinical Trial

Official title:

A Phase I Dose Escalation and Central Nervous System (CNS) Pharmacokinetic Study of the ErbB Family Inhibitor Afatinib in Patients With Recurrent or Progressive Brain Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02423525
• Other study ID #: 1200.229
• Secondary ID: 20161975
• Status: Completed
• Phase: Phase 1
• Start date: December 2016
• Est. completion date: August 2021

Study information

• Verified date: March 2022
• Source: Saint John's Cancer Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to try to determine the maximum safe dose of afatinib that can be administered to people with brain cancer. Other purposes of this study are to:

• find out what effects (good and bad) afatinib has;

• see how much drug gets into the body by collecting blood and cerebrospinal fluid for use in pharmacokinetic (PK) studies;

• learn more about how afatinib might affect the growth of cancer cells;

• look at biomarkers (biochemical features that can be used to measure the progress of disease or the effects of a drug).

Description:

This is an open-label, single institution, Phase I 3+3 dose escalation study to describe the safety and tolerability of afatinib in patients with brain cancer having failed prior therapy and to determine the recommended phase II dose.

Eligible patients will receive afatinib in treatment cycles of 28 days that will consist of afatinib administered orally by mouth once every four days. Patients will be assigned to the dose level open at the time of their enrollment. Patients will continue dosing of afatinib until disease progression, unacceptable toxicity, withdrawal of consent, or treating physician determines it is in their best interest to stop. Guidelines for modifying study drug doses is provided for the management of adverse treatment effects.

All patients will have regular evaluations for assessment of safety parameters as detailed in the study flow chart. Lumbar puncture and blood draw for assessing afatinib levels will occur as detailed in the study flow chart.

Neurological imaging and assessment for response will be performed approximately every eight weeks. Tumor response will be assessed according to Response Assessment in Neuro-Oncology (RANO) Working Group criteria.

An end of treatment evaluation will occur when a patient permanently discontinues study drug, as detailed in the study flow chart. Patients will then be followed every four months for survival.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 24
• Est. completion date: August 2021
• Est. primary completion date: August 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Diagnosis

1. Dose Escalation Cohorts: Histologically confirmed diagnosis of brain cancer:

1. glioblastoma (GBM),

2. anaplastic astrocytoma (AA),

3. anaplastic oligodendroglioma (AO),

4. anaplastic mixed oligoastrocytoma (AMO),

5. low grade gliomas,

6. brain metastases,

7. meningiomas,

8. leptomeningeal metastases

9. chordomas

10. pituitary tumors

11. medulloblastomas

2. Expansion Cohort: Histologically confirmed diagnosis of high-grade glioma with altered EGFR (e.g., amplification, mutation), including:

1. glioblastoma (GBM),

2. anaplastic astrocytoma (AA),

3. anaplastic oligodendroglioma (AO),

4. anaplastic mixed oligoastrocytoma (AMO)

• Has failed prior standard therapy including maximal safe surgical resection (when appropriate for the specific cancer type), radiation therapy (when appropriate for the specific cancer type), and systemic therapy (when appropriate for the specific cancer type).

• For diagnosis of GBM: has undergone maximal safe surgical resection, a course of postoperative radiation therapy with concurrent temozolomide, and maintenance temozolomide.

• For diagnosis of meningioma: has no other option of standard therapy such as surgical resection (partial or total resection) or radiation.

• Age 18 years and older.

• Karnofsky Performance Status = 60%.

• Adequate organ function, defined as all of the following:

1. Absolute neutrophil count (ANC) = 1.5 x 109/L.

2. Platelet count = 100 x 109/L.

3. Hemoglobin = 9.0 g/dL.

4. Total Bilirubin = 1.5 institution's upper limit of normal (ULN).

5. Aspartate amino transferase (AST) = 2.5 x institution's ULN.

6. Alanine amino transferase (ALT) = 2.5 x institution's ULN.

7. Alkaline phosphatase (ALP) = 2.5 x ULN unless considered tumor related.

• Recovered from any previous therapy-related toxicity to Grade 1 or to their clinical baseline at study entry.

• Women of child-bearing potential has negative serum or urine pregnancy test before the initiation of study drug dosing.

Exclusion Criteria:

• Insufficient time from prior therapy to study entry:

1. less than 28 days from whole-brain radiotherapy (WBRT) or stereotactic radiosurgery (SRS);

2. less than 28 days from any investigational agent;

3. less than 28 days from prior cytotoxic therapy (except 23 days from prior temozolomide, 14 days from vincristine (for GBM: 14 days from irinotecan or topotecan), 42 days from nitrosoureas, 21 days from procarbazine, irinotecan or topotecan administration);

4. less than 14 days from hormonal treatment

5. less than 7 days for non-cytotoxic agents, e.g., interferon, tamoxifen, thalidomide, cis-retinoic acid, etc.

6. When radiation necrosis is suspected, standard of care confirmatory imaging, such as MRI perfusion, magnetic resonance (MR) spectroscopy and or PET will be performed, and patients with findings consistent with radiation necrosis will be excluded.

• Current or anticipated use of enzyme-inducing anti-epileptic drugs (EIAED).

• Major surgery within 4 weeks before starting study treatment or scheduled for surgery during the projected course of the study.

• Known hypersensitivity to afatinib or its excipients.

• History or presence of clinically relevant cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure New York Heart Association (NYHA) classification of 3 or 4, unstable angina or poorly controlled arrhythmia, or myocardial infarction within 6 months prior to enrollment.

• Pregnant, nursing, or not using acceptable method of birth control.

• Any history of or concomitant condition that would compromise the patient's ability to comply with the study or interfere with the evaluation of the efficacy and safety of the test drug.

• Previous or concomitant malignancies at other sites, except effectively treated non-melanoma skin cancers, carcinoma in situ of the cervix, ductal carcinoma in situ or effectively treated malignancy that has been in remission for more than 3 years and is considered to be cured.

• Known pre-existing interstitial lung disease.

• Known active hepatitis B infection (defined as presence of Hep B sAg and/ or Hep B DNA), active hepatitis C infection (defined as presence of Hep C RNA) and/or known HIV carrier.

• Prior participation in a blinded afatinib clinical study, even if not assigned to afatinib treatment.

Related Conditions & MeSH terms

• Brain Cancer
• Brain Neoplasms

Intervention

Drug:
• Afatinib

Locations

Country	Name	City	State
United States	John Wayne Cancer Institute	Santa Monica	California

Sponsors (2)

Lead Sponsor	Collaborator
Santosh Kesari	Boehringer Ingelheim

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rate of dose limiting toxicities of pulsatile afatinib	Number of side effects of study treatment that prevent an increase in dose or level of that treatment	first 28 days of treatment
Primary	Maximum tolerated dose (MTD) of pulsatile afatinib	The highest dose evaluated that does not cause unacceptable side effects	first 28 days of treatment
Secondary	Treatment-emergent adverse events	Type, number, grade and seriousness of adverse events reported after the first dose of study treatment	7 months
Secondary	Afatinib levels in cerebrospinal fluid (CSF) and blood	Measurement of afatinib concentration in CSF and blood at defined timepoints	52 days
Secondary	Objective response rate as assessed by the RANO criteria	Tumor response compared to baseline as assessed by the RANO criteria	approximately 6 months to 1 year
Secondary	Best overall response rate	Best tumor response compared to baseline	approximately 6 months to 1 year
Secondary	Progression free survival	Time between the start of treatment to disease progression	up to 5 years
Secondary	Overall Survival	Time between the start of treatment to death	up to 5 years